# A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Source: https://onco.cc/trials/nct05624554/  
OnCo record `nct05624554` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) is a phase 3 interventional study registered as NCT05624554 by Merck Sharp & Dohme LLC, with 300 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2027-05-19. Interventions recorded: Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab and Truxima.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05624554
- Phase: 3
- Setting: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT05624554: https://clinicaltrials.gov/study/NCT05624554

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05624554.json